NEW YORK - IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 - 11, 2024, in Baltimore, MD and virtually.
Details of the oral presentation are as follows
Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression
Session Type: In-Person Oral Presentation
Session Title: Novel Production Platforms
Abstract Number: 282
Location: Ballroom 2
Presentation Date/Time: Friday, May 10th at 3:45 pm - 4:00 pm ET
Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation.
Contact:
Glenn Schulman
Tel: 203.494.7411
Email: gdschulman@IN8bio.com
Lee M. Stern
Email: lstern@meruadvisors.com
Kimberly Ha
Tel: 917.291.5744
Email: kimberly.ha@kkhadvisors.com
(C) 2024 Electronic News Publishing, source ENP Newswire